BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $120.
BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $120.